Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
AJNR Am J Neuroradiol ; 41(8): 1370-1376, 2020 08.
Article in English | MEDLINE | ID: covidwho-608376

ABSTRACT

Despite the severity of coronavirus disease 2019 (COVID-19) being more frequently related to acute respiratory distress syndrome and acute cardiac and renal injuries, thromboembolic events have been increasingly reported. We report a unique series of young patients with COVID-19 presenting with cerebral venous system thrombosis. Three patients younger than 41 years of age with confirmed Severe Acute Respiratory Syndrome coronavirus 2 (SARS-Cov-2) infection had neurologic findings related to cerebral venous thrombosis. They were admitted during the short period of 10 days between March and April 2020 and were managed in an academic institution in a large city. One patient had thrombosis in both the superficial and deep systems; another had involvement of the straight sinus, vein of Galen, and internal cerebral veins; and a third patient had thrombosis of the deep medullary veins. Two patients presented with hemorrhagic venous infarcts. The median time from COVID-19 symptoms to a thrombotic event was 7 days (range, 2-7 days). One patient was diagnosed with new-onset diabetic ketoacidosis, and another one used oral contraceptive pills. Two patients were managed with both hydroxychloroquine and azithromycin; one was treated with lopinavir-ritonavir. All patients had a fatal outcome. Severe and potentially fatal deep cerebral thrombosis may complicate the initial clinical presentation of COVID-19. We urge awareness of this atypical manifestation.


Subject(s)
Betacoronavirus , Coronavirus Infections/complications , Intracranial Thrombosis/etiology , Pneumonia, Viral/complications , Venous Thrombosis/etiology , Adult , Azithromycin/therapeutic use , COVID-19 , Coronavirus Infections/drug therapy , Female , Humans , Hydroxychloroquine/therapeutic use , Male , Pandemics , Pneumonia, Viral/drug therapy , Ritonavir/therapeutic use , SARS-CoV-2 , Venous Thrombosis/chemically induced , Young Adult , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL